,5,3Ј-Triiodo-L-thyronine (T3), but not L-thyroxine (T4), activated Src kinase and, downstream, phosphatidylinositol 3-kinase (PI3-kinase) by means of an ␣ v␤3 integrin receptor on human glioblastoma U-87 MG cells. Although both T 3 and T4 stimulated extracellular signal-regulated kinase (ERK) 1/2, activated ERK1/2 did not contribute to T 3-induced Src kinase or PI3-kinase activation, and an inhibitor of PI3-kinase, LY-294002, did not block activation of ERK1/2 by physiological concentrations of T 3 and T4. Thus the PI3-kinase, Src kinase, and ERK1/2 signaling cascades are parallel pathways in T 3-treated U-87 MG cells. T3 and T4 both caused proliferation of U-87 MG cells; these effects were blocked by the ERK1/2 inhibitor PD-98059 but not by LY-294002. Smallinterfering RNA knockdown of PI3-kinase confirmed that PI3-kinase was not involved in the proliferative action of T 3 on U-87 MG cells. PI3-kinase-dependent actions of T 3 in these cells included shuttling of nuclear thyroid hormone receptor-␣ (TR␣) from cytoplasm to nucleus and accumulation of hypoxia-inducible factor (HIF)-1␣ mRNA; LY-294002 inhibited these actions. Results of studies involving ␣v␤3 receptor antagonists tetraiodothyroacetic acid (tetrac) and Arg-Gly-Asp (RGD) peptide, together with mathematical modeling of the kinetics of displacement of radiolabeled T3 from the integrin by unlabeled T3 and by unlabeled T4, are consistent with the presence of two iodothyronine receptor domains on the integrin. A model proposes that one site binds T3 exclusively, activates PI3-kinase via Src kinase, and stimulates TR␣ trafficking and HIF-1␣ gene expression. Tetrac and RGD peptide both inhibit T3 action at this site. The second site binds T4 and T3, and, via this receptor, the iodothyronines stimulate ERK1/2-dependent tumor cell proliferation. T3 action here is inhibited by tetrac alone, but the effect of T4 is blocked by both tetrac and the RGD peptide. thyroid hormone; phosphatidylinositol 3-kinase; extracellular signal-regulated kinase 1/2; integrin ␣v␤3; glioblastoma cells; Src kinase; mitogenactivated protein kinase; intracellular hormone receptor trafficking ACTIONS OF THYROID HORMONE [L-thyroxine (T 4 ); 3,5,3Ј-triiodo-L-thyronine (T 3 )] that are independent of ligand binding to nuclear thyroid hormone receptors are called nongenomic actions. Nongenomic effects of thyroid hormone are initiated outside the cell nucleus but may culminate in complex cellular events that are nucleus mediated (7, 8, 26 -29). Initiation of nongenomic actions includes a plasma membrane receptor for T 4 and T 3 on integrin ␣ v ␤ 3 that is linked to mitogen-activated protein kinase [extracellular signal-regulated kinase (ERK) 1/2] for transduction of the hormone signal (3) and nuclear receptors residing in the cytosol of unstimulated cells, such as thyroid hormone receptor (TR) ␤1 (28).
thyroid hormone; phosphatidylinositol 3-kinase; extracellular signal-regulated kinase 1/2; integrin ␣v␤3; glioblastoma cells; Src kinase; mitogenactivated protein kinase; intracellular hormone receptor trafficking ACTIONS OF THYROID HORMONE [L-thyroxine (T 4 ); 3,5,3Ј-triiodo-L-thyronine (T 3 )] that are independent of ligand binding to nuclear thyroid hormone receptors are called nongenomic actions. Nongenomic effects of thyroid hormone are initiated outside the cell nucleus but may culminate in complex cellular events that are nucleus mediated (7, 8, 26 -29) . Initiation of nongenomic actions includes a plasma membrane receptor for T 4 and T 3 on integrin ␣ v ␤ 3 that is linked to mitogen-activated protein kinase [extracellular signal-regulated kinase (ERK) 1/2] for transduction of the hormone signal (3) and nuclear receptors residing in the cytosol of unstimulated cells, such as thyroid hormone receptor (TR) ␤1 (28) .
The phosphatidylinositol 3-kinase (PI3-kinase)/protein kinase B (Akt) pathway is an important regulator of cellular growth, metabolism, and survival (13, 19) . Studies of Storey et al. (38) indicate that T 3 activates PI3-kinase to slow the deactivation of potassium KCNH2 channels. Treatment of endothelial cells with T 3 increases the association of TR␣1 with the p85␣ subunit of PI3-kinase, leading to the phosphorylation and activation of Akt and endothelial nitric oxide synthase (16) . Furuya et al. (14) have also pointed out that the TR␤ mutant TR␤PV, via activation of the PI3-kinase-regulatory subunit p85␣, may affect PI3-kinase downstream signaling in both nuclear and extranuclear compartments, thus contributing to thyroid carcinogenesis. PI3-kinase appears to play a role in rapid nongenomic (15) and genomic actions of thyroid hormone (32) , even though the significance and molecular mechanisms of many of these nongenomic actions are incompletely understood. Src kinase, another integrin ␣ v ␤ 3 -regulated kinase, has also been reported to be involved in T 3 -induced Na-K-ATPase activation and expression in alveolar epithelial cells (22) .
In the current study, we have addressed the contributions of both ERK1/2 and PI3-kinase signal transduction pathways in the actions of T 4 and T 3 to specifically assess whether the cell proliferation effects of iodothyronines utilize both pathways. We find that both T 4 and T 3 activate ERK1/2 and cause cell proliferation, indicated by accumulation of proliferating cell nuclear antigen (PCNA) and radiolabeled thymidine incorporation, in a human glioma (U-87 MG) cell line that has been studied extensively by others (4, 21, 34, 42) . However, only T 3 causes tyrosine phosphorylation (activation) of PI3-kinase. This latter cell surface action of T 3 , however, does not contribute to cell proliferation; instead, its consequences include translocation of the nuclear hormone receptor, TR␣, from cytoplasm to the nucleus of hormone-treated cells and increased expression of the hypoxia-inducible factor (HIF)-1␣ gene.
Reagents and antibodies. T4, T3, tetraiodothyroacetic acid (tetrac), and Arg-Gly-Asp (RGD) and arginine-glycine-glutamate (RGE) peptides were obtained from Sigma Chemical (St. Louis, MO). Polyclonal rabbit antibodies to phospho (p)-ERK1/2, phospho-Src kinase (Y416), p85-PI3-kinase, and tyrosine-phosphorylated p85-PI3-kinase were purchased from Cell Signaling Technology (Beverly, MA), and monoclonal mouse anti-PCNA was purchased from Santa Cruz (Santa Cruz, CA). Goat anti-rabbit IgG and rabbit anti-mouse IgG were purchased from Dako (Carpenteria, CA). The chemiluminescence reagent was from ECL (Amersham, Piscataway, NJ), and the specific ERK1/2 activation inhibitor PD-98059, PI3-kinase inhibitor LY-294002, and Src inhibitor PP2 were obtained from Calbiochem (San Diego, CA). These inhibitors were added to cells 30 min before hormone addition.
Cell fractionation. Fractionation in a microfuge and preparation of nucleoproteins was by our previously reported methods (8, 27, 28) . Nuclear extracts were prepared by resuspension of the crude nuclei in high-salt buffer (hypotonic buffer containing 420 mM NaCl and 20% glycerol) at 4°C with rocking for 1 h. The supernatants were collected after subsequent centrifugation at 4°C and 13,000 revolutions/min for 10 min.
Transfection of siRNA. The small-interfering RNAs (siRNAs) of p85-PI3-kinase, ERK1, ERK2, and scrambled RNA (scRNA) were purchased from Santa Cruz. U-87 MG cells were seeded on six-well tissue culture plates at 60 -80% confluence and in the absence of antibiotic for 24 h before transfection. Immediately before transfection, the culture medium was removed, and the cells were washed one time with PBS and then transfected with either scRNA or siRNA (100 pM/well) using Lipofectamine (5 g/well) in Opti-MEM I medium according to the manufacturer's instructions (Ambion, Austin, TX). After transfection, cultures were incubated at 37°C for 4 h and then placed in fresh culture medium. After an additional 24 h, cells were used for experimentation.
Immunoblotting. The techniques have been standardized in our laboratory (8, 26 -28) and include separation of nucleoproteins on discontinuous SDS-PAGE followed by protein transfer to nitrocellulose membranes (Millipore, Bedford, MA). After being blocked with 5% milk in Tris-buffered saline containing 0.1% Tween, the membranes were incubated with various antibodies overnight. Secondary antibodies were either goat anti-rabbit IgG (1:1,000; Dako) or rabbit anti-mouse IgG (1:1,000; Dako), depending on the origin of the primary antibody. Immunoreactive proteins were detected by chemiluminescence, and blots were quantitated densitometrically. Immunoblot optical density results were expressed as the degree of increase compared with the corresponding untreated control sample. Combined results from triplicate experiments are shown Figs. 1-11 means Ϯ SE.
Confocal microscopy. Exponentially growing U-87 MG cells were seeded in chamber slides. After exposure to 0.25% hormone-stripped FBS-containing medium for 2 days, cells were treated with 10 Ϫ9 or 10 Ϫ7 M T3, with or without LY-294002 for 24 h. Cells were fixed with 4% formaldehyde in acetone for 30 min and then permeabilized in 0.06% Triton X-100 for 30 min. The cells were then incubated with polyclonal antibody to TR␣1 (Santa Cruz) followed by Alexa-488-labeled goat anti-mouse antibody (Molecular Probes, Eugene, OR), and the signal was revealed using the Histostain SP kit as recommended by the manufacturer (Zymed). Propidium iodide (Molecular Probes) was used to show nucleoprotein. Images of either TR␣1, nucleoprotein, or both are shown, in addition to a differential interference contrast image that demonstrates outlines of cellular plasma membranes and nuclear membranes.
RT-PCR. Total RNA was isolated as described previously (40) . First-strand cDNAs were synthesized from 1 g of total RNA using oligo(dT) and AMV Reverse Transcriptase. First-strand cDNA templates were amplified for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and HIF-1␣ mRNAs by PCR using a hot start (Ampliwax; Perkin-Elmer, Foster City, CA). Primer sequences were HIF1-␣ [5Ј-GCTCCCTATATCCCAATGGAT-3Ј (forward) and 5Ј-CCAT-CATGTTCCATTTTT-CGC-3Ј (reverse)] and GAPDH [5Ј-AAG-GTC-ATCCCTGAGGCTGAACG-3Ј (forward) and 5Ј-GGGT-GTCGCTGTTGAAGTCAGA-3Ј (reverse)]. The PCR cycle was an initial step of 95°C for 3 min, followed by 94°C for 1 min, 55°C for 1 min, 72°C for 1 min, then 25 cycles and a final cycle of 72°C for 8 min. PCR products were separated by electrophoresis through 2% agarose gels containing 0.2 g of ethidium bromide/ml. Gels were visualized under ultraviolet light and photographed with Polaroid film (Polaroid, Cambridge, MA). Photographs were scanned under direct light for quantitation and illustration. Results from PCR products were normalized to the GAPDH signal.
Thymidine incorporation. U-87 MG cells were seeded in 24-well trays and placed in medium containing 0.25% hormone-stripped FBS for 2 days. Cells were then placed in 10% hormone-stripped serumcontaining medium before experiments were started. Aliquots of cells were treated with reagents as indicated and incubated with 1 Ci [ 3 H]thymidine (final concentration, 13 nM) for 24 h. Cells were then washed two times with cold PBS; 5% trichloroacetic acid (TCA, 1 ml) was added, and the plate was held at 4°C for 30 min. The precipitate was washed two times with cold ethanol; 2% SDS (1 ml) was added to each well, and the TCA-precipitable radioactivity was quantitated in a liquid scintillation counter.
Radioligand binding assay. Membranes from U-87 MG cells were prepared by method as described previously (27) . The harvested cells were washed with PBS, harvested, and resuspended in icecold 250 mM sucrose, 10 mM HEPES, pH 7.5, 1 mM EDTA containing 10 g/ml aprotinin, 10 g/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride. The samples were centrifuged two times at 500 g for 15 min at 4°C. Na 2CO3 (100 mM) was added to the resulting supernatant and shaken for 45 min at 4°C, and then centrifuged at 100,000 g for 15 min. The pellet obtained was resuspended in 500 l of a buffer containing 250 mM sucrose, 10 mM HEPES, pH 7.5, and 1 mM MgCl 2 and separated into aliquots for future use. Protein content was quantitated using the Bio-Rad DC protein assay (Bio-Rad Laboratories, Hercules, CA), with BSA as a standard. Thyroid hormone binding displacement studies were performed as follows: stock solutions of T 3 and T4 were diluted to their final concentrations in 0.04 N KOH with 0.4% polyethylene glycol to ensure that the effect was independent of the solvent used. Purified cell membrane protein preparation (50 g) was mixed with 10 l of [ 125 I]T3 (2 Ci) for 10 min, and the indicated concentrations of test compounds were then added; the mixture was allowed to incubate an additional 30 min at room temperature. The mixtures were precipitated with 1 ml 5% TCA at 4°C for 30 min. The precipitate was then washed two times with cold ethanol, and the resulting TCA-precipitable radioactivity was quantitated in a liquid scintillation counter.
Quantitation of results and statistical analysis. Immunoblot densities were measured with a Storm 860 phosphorimager followed by analysis with ImageQuant software (Molecular Dynamics, Sunnyvale, CA). Unpaired Student's t-test, with P Ͻ 0.05 as the threshold for significance, was used to evaluate the significance of the hormone and inhibitor effects.
Mathematical modeling of the binding site-ligand interactions was by nonlinear least-square regression, using the ADAPT II package of programs of D'Argenio and Schumitzky (6) . Weight was as the inverse of the point estimate of the observation variance to best approximate the homoscedastic assumptions. The Akaike Information Criterion was calculated for both one-and two-site models, and discrimination was based on an F-test.
RESULTS

Thyroid hormones activate diverse signal transduction pathways in human glioma U-87 MG cells. In cells treated with 10
Ϫ10 to 10 Ϫ6 M T 3 , ERK1/2 activation and cellular PCNA accumulation were seen in nuclear fractions (Fig. 1A) . Cytosolic PI3-kinase accumulation and tyrosine phosphorylation of p85-PI3-kinase were induced by T 3 . In addition, total cellular Src kinase phosphorylation was increased although total Src kinase did not change (Fig. 1A ). These effects of T 3 were hormone concentration-dependent.
After In additional studies, the responses of U-87 MG cells to T 4 and T 3 separately or together were examined. Although the addition of T 4 to T 3 enhanced the effect on pERK1/2 accumulation, there was no enhancement or inhibition of the T 3 effect on cell proliferation or pTyr-p85-PI3-kinase levels in cells also treated with T 4 (Fig. 2) .
Role of integrin ␣ v ␤ 3 in thyroid hormone-induced signal transduction activation. We have previously shown that T 4 , via binding to cell membrane integrin ␣ v ␤ 3 , activates ERK1/2 and that this activation can be blocked by an RGD peptide (3, 8) .
To examine the role of integrin ␣ v ␤ 3 in T 3 -induced activation of ERK1/2 and PI3-kinase, U-87 MG cells were incubated with RGD or RGE peptide for 30 min before treatment with 10 Ϫ9 M T 3 for 30 min. ERK1/2 activation was induced by T 3 , but this effect was not inhibited by preincubation with either RGD or RGE peptides (Fig. 3A) . Levels of PCNA accumulation in T 3 -treated cells were also unaffected by the peptides. In contrast, activation of PI3-kinase and Src kinase by T 3 was blocked by preincubation with the RGD peptide although levels of ERK1/2 activation and PCNA accumulation remained the same (Fig. 3A) . These observations are consistent with the existence of two discrete binding sites for T 3 on the integrin, one of which activates PI3-kinase and the second of which is linked to ERK1/2 activation.
Further studies were carried out with the thyroid hormone analog tetrac, which, like the RGD peptide, also inhibits thyroid hormone binding to integrin ␣ v ␤ 3 (3, 8) . Tetrac alone did not induce ERK1/2 activation, cell proliferation. or tyrosine phosphorylation of PI3-kinase and Src kinase (Fig. 3B) . Addition of tetrac (10 Ϫ9 M) to cells pretreated with T 3 (10 Ϫ9 M) resulted in inhibition of T 3 -induced ERK1/2 activation and PCNA expression, as well as inhibition of PI3-kinase and Src activation (Fig. 3B) . As anticipated from our previous studies (3, 7, 8) , T 4 -stimulated cell proliferation and ERK1/2 activation were completely blocked by tetrac (Fig. 3B) .
To examine further the possibility that T 3 shares a cell surface binding site with T 4 , 50 g of plasma membrane protein/sample were incubated with [ 125 I]T 3 for 10 min, and varying concentrations of unlabeled T 4 or T 3 were then added. Bound/free separation was by protein precipitation. Membrane-bound radiolabeled T 3 was displaced by unlabeled T 4 in a concentration-dependent manner (Fig. 4A) , and unlabeled T 3 was also effective in displacing [
125 I]T 3 binding to U-87 MG plasma membranes (Fig. 4B) . Statistical modeling by F-test of the binding data shown in Fig. 4 Fig. 5A ). In parallel studies of cytosol fractions, PI3-kinase phosphorylation by 10 Ϫ9 M T 3 , but not by T 4 , occurred in U-87 MG cells, and PD-98059 did not block that T 3 -induced effect (Fig. 5A ), indicating that ERK1/2 activation does not contribute to PI3-kinase activation. Activation of Src by T 3 was similarly unaffected by inhibition of ERK1/2 activation.
Transfection with ERK1/2 siRNA was used to further confirm that ERK1/2 activation does not play a role in T 3 -induced PI3-kinase activation. Results presented in Fig.  5B indicate that nuclear ERK1/2 decreased by 60% in ERK1/2 siRNA-transfected cells exposed to T 3 compared with levels in cells transfected with scRNA, as measured in three experiments. There was no difference in PI3-kinase activation by 10 Ϫ9 or 10 Ϫ7 M T 3 when comparing scRNAand ERK1/2 siRNA-transfected cells, indicating again that activation of ERK1/2 is not essential for T 3 -induced PI3-kinase activation.
In further experiments, we examined the possible role of PI3-kinase in ERK1/2 activation and PCNA expression. activation in the presence of T 3 or T 4 (Fig. 5C ). In contrast, PI3-kinase phosphorylation by T 3 was inhibited by LY-294002, although Src phosphorylation was not affected by the LY-294002 compound. However, T 3 -induced PCNA expression was increased by the PI3-kinase inhibitor (Fig. 5C ). When cells were pretreated with the Src activation inhibitor PP2, PI3-kinase activation by T 3 was blocked, as shown in Fig. 5D . Thymidine incorporation studies comparing the results of T 4 and T 3 in the presence of the inhibitors PD-98059 or LY-294002 support the PCNA results presented above: cell proliferation in T 3 -treated cells did not change with the addition of LY (Fig. 6, lanes 2 and 3 compared with lanes 6 and 7) , whereas T 4 -induced thymidine uptake increased in the presence of LY-294002 (Fig. 6, lane 8) . In contrast, PD-98059 partially suppressed thymidine incorporation by both T 4 and T 3 because of the dependence of the proliferative action of both hormones on ERK1/2 activation.
The minimal role of PI3-kinase in cell proliferation was further confirmed in cells transfected with siRNA of the p85-PI3-kinase regulatory domain. Results of these studies demon- Fig. 3 . Effect of an Arg-Gly-Asp (RGD) peptide and the thyroid hormone analog tetraiodothyroacetic acid (tetrac) on thyroid hormone-induced cell proliferation, ERK1/2 activation, and activation of Src kinase and PI3-kinase. A: U-87 MG cells were treated with 500 nM RGD or arginine-glycine-glutamate (RGE) peptide for 30 min before addition of T3, 10 Ϫ9 M, either for another 30 min (for detection of PI3-kinase and ERK1/2) or for 24 h (for detection of PCNA). The RGD peptide blocked T3-induced PI3-kinase and Src kinase phosphorylation (two bars on right, P Ͻ 0.01), whereas it did not block T3-induced ERK1/2 activation or cell proliferation. The RGE peptide was not inhibitory. B: U-87 MG cells were treated with either 10 Ϫ7 M T4 or 10 Ϫ9 M T3, in the presence or absence of 10 Ϫ9 or 10 Ϫ7 M tetrac, which interferes with hormone binding to integrin ␣v␤3. Tetrac was added to the media 30 min before the addition of T3 or T4. Tetrac inhibited ERK1/2 activation and cell proliferation (PCNA) by T3, 10 Ϫ9 M (P Ͻ 0.05), as well as PI3-kinase and Src kinase phosphorylation by T3 (P Ͻ 0.01). Tetrac had similar effects on T4-stimulated ERK1/2 activation and cell proliferation (PCNA) (P Ͻ 0.05). Neither T4 nor tetrac alone promoted activation of PI3-kinase and Src kinase. strate decreased cytosolic p85-PI3-kinase in both the presence and absence of T 3 in siRNA-transfected cells but no effect of this reduction on stimulation of cell proliferation by T 3 , as measured by PCNA immunoblot (Fig. 7) .
T 3 -induced PI3-kinase activation causes nuclear accumulation of TR␣. We examined PI3-kinase-dependent biological activities induced by T 3 in U-87 MG cells, specifically, the movement of the thyroid hormone receptor, TR␣, from cytosol to nuclei of treated cells. Cells were exposed to T 3 , 10 Ϫ9 or 10 Ϫ7 M, in the presence or absence of the inhibitor LY-294002 for 24 h; cells were then examined by confocal microscopy. The appearance of TR␣ in nuclei was indicated by the superimposition of the receptor color (green) and nucleoprotein color (red) to form a yellow color (Fig. 8) . T 3 , 10 Ϫ7 M, caused nuclear accumulation of TR␣, whereas 10 Ϫ9 M T 3 was less effective (Fig. 8A) . In the presence of LY-294002, however, TR␣ was not evident in T 3 -treated cell nuclei, indicating the PI 3-kinase-dependent nature of this response. Results of these microscopic studies were confirmed by immunoblotting of nucleoproteins with TR␣ antibody (Fig. 8B) , again showing that TR␣ translocation to nuclei relates directly to T 3 activation of PI3-kinase.
Neither PD-98059 (Fig. 9A ) nor siRNA-ERK1/2 ( Fig. 9B ) affected T 3 -induced nuclear accumulation of TR␣. In contrast, 10 Ϫ7 M T 4 had no effect on TR␣ translocation but did induce ERK1/2-dependent TR␤1 nuclear accumulation (Fig.  9A) . PD-98059 inhibited T 4 -stimulated nuclear accumulation of TR␤1, as we have demonstrated previously (28) . At concentrations of 10 Ϫ9 and 10 Ϫ7 M, T 3 did not promote translocation of TR␤1 to the nucleus (Fig. 9A) . At higher concentrations of 10 Ϫ6 or 10 Ϫ5 M, however, T 3 does promote nuclear accumulation of TR␤1 (results not shown), as reported by others (2) .
PI3-kinase activation is required for T 3 -induced expression of the HIF-1␣ gene.
The role of PI3-kinase in the expression of selected thyroid hormone-inducible genes has also been examined. U-87 MG cells were treated with 10 Ϫ9 or 10 Ϫ7 M T 3 in the presence or absence of the PI3-kinase inhibitor LY-294002. Results from a representative experiment, presented in Fig. 10A , indicate that HIF-1␣ expression was induced by T 3 and that this action was PI3-kinase-dependent. HIF-1␣ gene expression has been shown by Moeller and coworkers (32, 33) to be nongenomically modulated by T 3 . We further examined the role of ERK1/2 activation on thyroid hormone-induced HIF-1␣ expression, and results indicated that PD-98059 did not affect the expression of HIF-1␣ induced by T 3 (Fig.  10B) . Of interest was that PD did inhibit the stimulatory effect of T 4 on HIF-1␣ expression; we have previously demonstrated that T 4 -induced gene expression, mediated via TR␤1, is inhibited by PD-98059 (28) .
DISCUSSION
The genomic actions of thyroid hormone involve primary interaction of the hormone T 3 in the cell nucleus with a heterodimer of TR␤1 and another member of the superfamily of hormone receptors such as retinoid X receptor to initiate transcription of thyroid hormone-responsive genes (41) . The process involves the shedding of corepressor proteins and the recruitment of coactivators (1, 25) . Nongenomic actions of thyroid hormone include changes in activity of ion pumps in the plasma membrane (9, 18) , changes in cytosolic signaling initiated at the plasma membrane (3, 8 -12) , actions that involve mitochondria (31) , and stimulation of intracellular protein trafficking from cytosol or organelles into the nucleus (10, 28, 39) .
Complex interfaces of nongenomic and genomic mechanisms of thyroid hormone action have also been described (11) . These include activation at the cell surface by thyroid hormone of the ERK1/2 signal transduction pathway and subsequent ERK1/2-dependent phosphorylation of specific serines of nucleoproteins. Among the proteins involved are TR␤1 (28), the nuclear estrogen receptor-␣ (39), and p53 (37) .
Another example of interplay between nongenomic and genomic mechanisms is activation of PI3-kinase in cytoplasm by direct interaction of thyroid hormone-liganded, extranuclear TR␣1 with the p85 regulatory subunit of the kinase, resulting in transcription of a number of specific genes (16). Lei et al. have implicated Src (22) , PI3-kinase (22, 23) and ERK1/2 (24) in the nongenomic action of T 3 on insertion of Na-K-ATPase units into the plasma membrane and enhancement of the activity of the sodium pump. An additional example of nongenomic/genomic cross talk is thyroid hormone-stimulated cell proliferation. The latter is ERK1/2-dependent, requires new blood vessel formation (7), and has been described in human breast cancer cells (39) and glioma cells (8) .
We have recently described a plasma membrane receptor for T 4 and T 3 on integrin ␣ v ␤ 3 (3). Thyroid hormone binding at this receptor has been shown to activate ERK1/2 and promote angiogenesis (7) and cell proliferation (8) . That a receptor for thyroid hormone might exist on an integrin was suggested more than a decade ago by Farwell et al. (12) in studies of glial cells. Tetrac is a deaminated T 4 analog that has no agonist function at the integrin receptor but blocks hormone-binding at this site and suppresses the proliferative activity of thyroid hormone on cancer cells (8) . Tetrac is therefore a probe of the involvement of the integrin receptor in cellular actions of thyroid hormone. An RGD peptide provides an additional probe, since the hormone receptor is at or near the RGD recognition site on the integrin (3, 8) that is critical to the binding of extracellular matrix proteins by the integrin (36) .
Reports from other laboratories have implicated several kinases, including ERK1/2, Src kinase, and PI3-kinase, in the nongenomic mechanisms of thyroid hormone action (22, 24, 33) . Integrin ␣ v ␤ 3 is known to activate Src (17) . Against this background, we conducted the present experiments to compare the ability of T 4 and T 3 to activate via ␣ v ␤ 3 the ERK1/2, Src kinase, and PI3-kinase signal transduction cascades. We also determined whether ERK1/2 and PI3-kinase both contribute to the proliferative activity of thyroid hormone. These studies carried out in a human glioblastoma cell line confirm that both T 4 and T 3 activate the ERK1/2 pathway and cause cell proliferation, whereas only T 3 is also capable of enhancing Src kinase and PI3-kinase activities. Because both hormone analogs interact with the integrin receptor (3), this observation suggests that the receptor domain can discriminate between T 4 and T 3 . Further support for this conclusion was the observation that tetrac inhibited pERK1/2 activation (nuclear accumulation) and cancer cell proliferation by both T 4 and T 3 , whereas the RGD peptide inhibited the action of T 4 , but not that of T 3 , on ERK1/2 activation and cell proliferation. The RGD peptide did, however, block activation by T 3 of Src kinase and PI3-kinase, suggesting that there may be two integrin binding sites for T 3 , as shown schematically in Fig. 11 .
We also determined the kinetics of displacement of radiolabeled T 3 from the membrane receptor domain by unlabeled T 4 and by unlabeled T 3 . Mathematical modeling of the results of these displacement studies by one of the authors (Drusano) significantly favored the existence of two sites capable of binding T 3 , only one of which also bound T 4 . Thus several lines of evidence (modeling of the kinetics of binding of T 3 and T 4 , differential activation of PI3-kinase and of ERK1/2 by T 3 and T 4 , and binding inhibitor studies with RGD peptide and tetrac) infer the existence of two T 3 -binding sites on the integrin, one of which is shared with T 4 .
When we looked downstream of the receptor to cell proliferation; using either PCNA accumulation or labeled thymidine incorporation, we observed that both T 4 and T 3 were proliferative factors for glioblastoma cells via an ERK1/2-dependent pathway. T 3 , but not T 4 , was found to be capable of activating Ϫ9 M T3 or 10 Ϫ7 M T4 for 30 min (for detection of ERK1/2, PI3-kinase, and Src kinase activation) or for 24 h (for detection of PCNA). A representative study of nuclear fractions shows that both T3 and T4 stimulated ERK1/2 activation and cell proliferation, and that this stimulation was inhibited by PD (P Յ 0.02). In a parallel study of cytosol fractions, T3, but not T4, induced PI3-kinase phosphorylation. T3 also induced Src kinase activation in a whole cell lysate preparation. PD did not inhibit T3-induced phosphorylation of PI3-kinase and Src but did suppress PCNA expression and ERK1/2 activation by T3 (P Ͻ 0.01). B: U-87 MG cells were transfected with ERK1/2 small-interfering RNA (siRNA) or scrambled RNA (scRNA), and responses to T3 were then studied. Cells with scRNA (3 lanes in middle) responded to T3 in a manner similar to untreated cells (3 lanes on left). Cells containing ERK1/2 siRNA, however, showed no cell proliferation and little ERK1/2 activation in response to T3 as seen in representative immunoblots at top. PI3-kinase activation, however, was unchanged (3 lanes on right), indicating again that T3 stimulation of PI3-kinase activation is independent of ERK1/2 activation. C: U-87 MG cells were pretreated with LY-294002 (LY, 1.4 M) for 30 min before the addition of T4 or T3 for 30 min (for kinase activation) or for 24 h (for PCNA expression). Treatment with LY-294002 reduced 10 Ϫ9 M T3-stimulated cytosolic PI3-kinase phosphorylation (P Ͻ 0.05) but did not diminish nuclear ERK1/2 activation and cell proliferation by either hormone. LY-294002 did not alter T3-stimulated Src kinase phosphorylation. D: cells were pretreated with the Src kinase inhibitor PP2 (10 M) for 30 min before the addition of T3, 10 Ϫ9 or 10 Ϫ7 M. T3-induced tyrosine phosphorylation of PI3-kinase was inhibited by PP2 (P Ͻ 0.02 at both T3 concentrations). PI3-kinase, and this led to nonproliferative downstream functions, i.e., trafficking of TR␣ and expression of HIF-1␣. Thus there was segregation of downstream consequences of hormone action initiated at the plasma membrane. Tetrac and RGD peptide are two inhibitors of binding of iodothyronines to the integrin receptor (3, 8, 11) whose application in the current studies clarified the distinction between the two T 3 binding sites.
In Fig. 11 , we propose a two-site model of the actions of thyroid hormone at the receptor domain of integrin ␣ v ␤ 3 . At one site (S1), T 3 alone is bound and activates Src kinase and PI3-kinase; this leads to nuclear uptake of TR␣ and transcription of HIF-1␣. Tetrac and RGD peptide are inhibitors at this site. At site S2, T 4 and T 3 act via ERK1/2 activation to cause tumor cell proliferation. The effects of tetrac and RGD peptide are discrete at S2; both block cell proliferation caused by T 4 , whereas only tetrac inhibits the proliferative, ERK1/2-dependent effect of T 3 . In this model, we assume that the binding of T 3 and T 4 has different allosteric consequences at the receptor site.
Recent reports of the participation of extranuclear TR␣ (11, 16) in nongenomic actions of iodothyronines were the rationale for our focus on the trafficking of TR␣ in thyroid hormonetreated U-87 MG cells. Our confocal microscopy studies revealed that the TR␣ receptor moved from cytoplasm to the nucleus of T 3 -treated cells and that LY-294002 inhibited that trafficking, indicating that the process was PI3-kinase-dependent. That the trafficking promoted by T 3 , compared with T 4 , may affect different proteins was shown above by the translo- cation of TR␣ from the cytosol to the nucleus in response to T 3 , but not in response to T 4 . In contrast, trafficking of TR␤1 from cytosol to nucleus is more responsive to cell treatment with T 4 , as shown in Fig. 9A , and is dependent on ERK1/2 activation, as we have described previously (28) . Treatment with T 3 (10 Ϫ6 M), however, has been found to cause movement of TR␤1 from cytoplasm into the nucleus, as Baumann et al. (2) have shown.
The induction of HIF-1␣ expression by T 3 was included in the present studies as a nongenomically initiated endpoint of thyroid hormone action because of a recent description of this mechanism (32, 33) . This effect of the hormone is an example of the genomic consequences of a nongenomic action of the hormone. In the original description, this T 3 action was seen to be initiated in cytoplasm (32) , but the present studies offer the possibility that the plasma membrane integrin receptor for thyroid hormone may be involved in the hormonal effect.
These observations provide novel insights into both the complex transduction of thyroid hormone signals by the ERK1/2 and PI3-kinase pathways and the nongenomic activities of T 3 and T 4 . From a cell surface integrin receptor, T 3 may Ϫ7 M T4 caused nuclear accumulation of TR␤1, but no effect on TR␣ location in cells. The addition of PD-98059 did inhibit the T4 effect, as we have reported previously (37) . B: U-87 MG cells transfected with ERK1/2 siRNA or scRNA were treated with 10 Ϫ9 or 10 Ϫ7 M T3 for 24 h. Lane 4 provides a normalized control value of 1 for lanes 5 and 6, and lane 7 for lanes 8 and 9. Comparing results in lanes 4 -6 (scRNA) with those in lanes 7-9 (siRNA), it is again apparent that ERK1/2 activation does not play a principal role in the intracellular transfer of TR␣ to the nucleus in the presence of T3. regulate very specific gene transcription via PI3-kinase; others have also implicated PI3-kinase in nongenomic induction of gene transcription (22-24, 32, 33) , although not from an initiation point on the cell surface. In the current studies, T 3 also stimulated tumor cell proliferation, as did T 4 , via an ERK1/2-dependent mechanism that was PI3-kinase-independent. However, it is important to acknowledge that, in other cancer cell systems, PI3-kinase may be integral to the action of proliferative factors other than thyroid hormone (20) . Fig. 11 . Proposed pathways by which thyroid hormones promote U-87 MG cell proliferation and intracellular trafficking of the thyroid hormone receptors TR␣ and TR␤1. Two hormone-binding sites [site 1 (S1) and site 2 (S2)] are proposed within the iodothyronine receptor domain on integrin ␣v␤3. L-T3 (T3) interacts with S1 to activate the PI3-kinase signal transduction pathway via Src kinase activation. Downstream consequences are shuttling of cytoplasmic TR␣ to the nucleus and transcription of the HIF-1␣ gene. T3-initiated action at S1 is inhibited by tetrac and the RGD peptide. Inhibition of PI3-kinase activation by LY-294002 downstream of Src blocks TR␣ shuttling and HIF-1␣ transcription, and inhibition of Src kinase activation by PP2 prevents hormone activation of PI3-kinase and consequent cellular actions. Proliferation of U-87 MG cells in response to T3 is unaffected by this pathway. L-T4 (T4) and T3 both bind to S2 to cause ERK1/2-dependent U-87 MG cell proliferation, and this effect is blocked by the ERK1/2 inhibitor PD-98059. The T4 effect on cell proliferation is inhibited by both tetrac and RGD peptide, but the action of T3 on cell proliferation via S2 is inhibited only by tetrac. This may reflect allosteric changes in the integrin site that are distinctive for the liganding of T3 and T4. At S2, the disproportionate sizes of "T4" and "T3" reflect the greater effectiveness of T4 at this site in terms of TR␤1 trafficking and cell proliferation.
